Antabio is a privately-held clinical-stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments for drug-resistant infections due to CDC and WHO critical priority pathogens.
The company has a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. Antabio’s lead program, MEM-ANT3310, is being developed for the treatment of hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE).
The company’s portfolio includes two further programs: 1) ANT3273, a groundbreaking (novel class, novel mode of action) inhalation treatment of Pseudomonas aeruginosa (PA) infections, particularly those affecting patients with chronic pulmonary diseases (e.g. Bronchiectasis, Cystic Fibrosis, COPD), and 2) MEM-ANT2681, a novel and potent metallo ß-lactamase (MBL) inhibitor to be combined with meropenem for the treatment of MBL-producing carbapenem-resistant Enterobacterales (CRE), particularly New Delhi Metallo ß-lactamase (NDM) carrying strains.
Antabio has built an international team with highly successful track records, including former executives/managers from Novexel, Merck, GSK and Astra Zeneca.
The company has an impressive track record in attracting non-dilutive funding, including multi-million € awards from the Wellcome Trust, CARB-X, and ARPEGE.
